恒瑞医药公告,公司子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》,公司瑞普泊肽注射液的药品上市许可申请获国家药监局受理。此次申报上市,是基于两项瑞普泊肽注射液在成人2型糖尿病(T2DM)患者中开展的多中心、随机、对照的关键Ⅲ期临床研究,即PRIME-1研究和PRIME-2研究。瑞普泊肽是恒瑞医药自主研发的胰高血糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素肽(GIP)双...
Source Link恒瑞医药公告,公司子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》,公司瑞普泊肽注射液的药品上市许可申请获国家药监局受理。此次申报上市,是基于两项瑞普泊肽注射液在成人2型糖尿病(T2DM)患者中开展的多中心、随机、对照的关键Ⅲ期临床研究,即PRIME-1研究和PRIME-2研究。瑞普泊肽是恒瑞医药自主研发的胰高血糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素肽(GIP)双...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.